The FDA has approved Guardant360 Liquid CDx, a blood-based test that integrates genomic and epigenomic profiling for advanced cancer, offering a broader genomic footprint and faster results.
Illumina’s FDA-approved TruSight Oncology test will be reimbursed by CMS at $2,989.55 per test starting Jan. 1, 2026, enabling broader laboratory access to genomic profiling for Medicare beneficiaries.
Labcorp's new strategic service offerings in its precision oncology portfolio enhance its role as a partner for biopharmaceutical companies.
Proteomics technology company SomaLogic signed a licensing agreement with OncoHost to develop new cancer diagnostics solutions.
Read More
The study aims to enables access to comprehensive genetic and genomic testing for advanced cancer patients in underserved communities.
Read More
Foundation Medicine announced a partnership to integrate its comprehensive genomic profiling (CGP) and other testing services with Epic’s EMR.
Read More
OmniSeq Insight is a pan-cancer, solid tumor test that combines two different treatment paradigms: genomic and immune profiling.
Read More
This companion diagnostic for multiple hematologic indications will be the first to use TSO 500 with peripheral whole blood as a diagnostic sample type.
Read More
GenomOncology and UH Seidman Cancer Center enter into a partnership to increase clinical trial accrual rates.
Read More
Illumina has established oncology partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to expand the reach of TruSight Oncology.
Read More
Sema4 Signal provides precision oncology solutions with advanced analytics, digital tools, and exome-based somatic and hereditary cancer genomic tests.
Read More